Literature DB >> 24016786

New antiplatelet agents for cardiovascular disease.

Doson Chua, Cesilia Nishi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24016786      PMCID： PMC3826361          DOI： 10.1503/cmaj.130033

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  33 in total

Review 1.  Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.

Authors:  Jeremy S Paikin; Douglas S Wright; Mark A Crowther; Shamir R Mehta; John W Eikelboom
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

2.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

Authors:  Tomas Jernberg; Christopher D Payne; Kenneth J Winters; Christelle Darstein; John T Brandt; Joseph A Jakubowski; Hideo Naganuma; Agneta Siegbahn; Lars Wallentin
Journal:  Eur Heart J       Date:  2006-04-18       Impact factor: 29.983

3.  Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Authors:  Deepak L Bhatt; Gregg W Stone; Kenneth W Mahaffey; C Michael Gibson; P Gabriel Steg; Christian W Hamm; Matthew J Price; Sergio Leonardi; Dianne Gallup; Ezio Bramucci; Peter W Radke; Petr Widimský; Frantisek Tousek; Jeffrey Tauth; Douglas Spriggs; Brent T McLaurin; Dominick J Angiolillo; Philippe Généreux; Tiepu Liu; Jayne Prats; Meredith Todd; Simona Skerjanec; Harvey D White; Robert A Harrington
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 91.245

4.  Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Authors:  Z M Chen; L X Jiang; Y P Chen; J X Xie; H C Pan; R Peto; R Collins; L S Liu
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

5.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

9.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-31       Impact factor: 29.690

10.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Authors:  Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245
View more
  5 in total

1.  A pharmacist's guide to the 2012 update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy.

Authors:  Margaret L Ackman; Claudia Bucci; Michael Callaghan; Heather Kertland; Chantal Pharand; Patrick Robertson; William Semchuk
Journal:  Can Pharm J (Ott)       Date:  2015-03

2.  Not quite the full story on new antiplatelets.

Authors:  Cait O'Sullivan; Aaron M Tejani
Journal:  CMAJ       Date:  2014-04-15       Impact factor: 8.262

3.  Not quite the full story on new antiplatelets.

Authors:  Doson Chua; Cesilia Nishi
Journal:  CMAJ       Date:  2014-04-15       Impact factor: 8.262

4.  For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2019-12-01

5.  The norpurpureine alkaloid from Annona purpurea inhibits human platelet activation in vitro.

Authors:  Gabriela Sánchez; Omar Estrada; Giovana Acha; Alfonso Cardozo; Franshelle Peña; Marie Christine Ruiz; Fabián Michelangeli; Claudia Alvarado-Castillo
Journal:  Cell Mol Biol Lett       Date:  2018-04-18       Impact factor: 5.787
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.